Vila Estapé Jordi, Zboromyrska Yuliya, Vergara Gómez Andrea, Alejo Cancho Izaskun, Rubio García Elisa, Álvarez-Martínez Miriam José, la Bellacasa Brugada Jorge Puig de, Marcos Maeso M Ángeles
Servicio de Microbiología, Centro de Diagnóstico Biomédico, Hospital Clínic, ISGlobal, Centre for International Health Research (CRESIB), Barcelona, España.
Servicio de Microbiología, Centro de Diagnóstico Biomédico, Hospital Clínic, ISGlobal, Centre for International Health Research (CRESIB), Barcelona, España.
Enferm Infecc Microbiol Clin. 2016 Jul;34 Suppl 3:40-6. doi: 10.1016/S0213-005X(16)30218-X.
Lower respiratory tract infections remain one of the most common causes of mortality worldwide, which is why early diagnosis is crucial. Traditionally the microbiological diagnosis of these infections has been based on conventional methods including culture on artificial media for isolation of bacteria and fungi and cell cultures for virus and antibody or antigen detection using antigen-antibody reactions. The main drawback of the above mentioned methods is the time needed for an etiological diagnosis of the infection. The techniques based on molecular biology have drawn much attention in recent decades as tools for rapid diagnosis of infections. Some techniques are very expensive, especially those that can detect various microorganisms in the same reaction, therefore the question that arises is whether the cost of such testing is justified by the information obtained and by the clinical impact that its implementation will determine. In this article we make a review of the various techniques of molecular biology applied to the diagnosis of pneumonia and focus primarily on analysing the impact they may have on the management of patients with acute respiratory tract infections.
下呼吸道感染仍然是全球最常见的死亡原因之一,这就是早期诊断至关重要的原因。传统上,这些感染的微生物学诊断基于常规方法,包括在人工培养基上培养以分离细菌和真菌,以及使用抗原 - 抗体反应进行病毒、抗体或抗原检测的细胞培养。上述方法的主要缺点是感染病因诊断所需的时间。近几十年来,基于分子生物学的技术作为感染快速诊断工具受到了广泛关注。一些技术非常昂贵,尤其是那些能够在同一反应中检测多种微生物的技术,因此出现的问题是,这种检测的成本是否能由所获得的信息以及其实施将决定的临床影响来证明是合理的。在本文中,我们对应用于肺炎诊断的各种分子生物学技术进行了综述,并主要侧重于分析它们对急性呼吸道感染患者管理可能产生的影响。